{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:45:28Z","timestamp":1775094328121,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[1999,12,1]],"date-time":"1999-12-01T00:00:00Z","timestamp":944006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[1999,12]]},"DOI":"10.4065\/74.12.1239","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:16:10Z","timestamp":1232759770000},"page":"1239-1254","source":"Crossref","is-referenced-by-count":17,"title":["Medical Treatment of Later-Stage Motor Problems of Parkinson Disease"],"prefix":"10.4065","volume":"74","author":[{"given":"J. Eric","family":"Ahlskog","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4065\/74.12.1239_bib1","first-page":"523","article-title":"Motor complications of chronic levodopa therapy in Parkinson's disease","volume":"20","author":"Miyawaki","year":"1997","journal-title":"Clin Nettro-pharmacol"},{"key":"10.4065\/74.12.1239_bib2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0025-6196(11)63004-8","article-title":"Treatment of early Parkinson's disease: arc complicated strategics justified?","volume":"71","author":"Ahlskog","year":"1996","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/74.12.1239_bib3","series-title":"Parkinson's Disease: The Treatment Options","first-page":"93","article-title":"Neuroproieelive strategies in the treatment of Parkinson's disease; clinical evidence","author":"Ahlskog","year":"1999"},{"key":"10.4065\/74.12.1239_bib4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0140-6736(05)70285-3","article-title":"Adverse reactions to levodopa: drug toxicity or progression of disease?","volume":"351","author":"Agid","year":"1998","journal-title":"Lancet"},{"key":"10.4065\/74.12.1239_bib5","first-page":"231","article-title":"L-dopa therapy of Parkinson's disease: plasma L.-dopa concentration, therapeutic response, and side effects","volume":"46","author":"Mucnter","year":"1971","journal-title":"Mayo Clin Prac"},{"key":"10.4065\/74.12.1239_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1056\/NEJM198402233100802","article-title":"The \u201con-off\u201d phenomenon in Parkinson's disease: relation to levodopa absorption and transport","volume":"310","author":"Nult","year":"1984","journal-title":"N Engl J Med"},{"key":"10.4065\/74.12.1239_bib7","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.35.7.949","article-title":"Permanent human parkinsonism due to l-Methyl-4-phcnyl-1,2,3,6-lctrahydropyridine (MPTP): seven cases","volume":"35","author":"Ballurd","year":"1985","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib8","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/jnnp.49.8.853","article-title":"Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography","volume":"49","author":"Leenders","year":"1986","journal-title":"J Neural Neurosurg Psychiatry"},{"key":"10.4065\/74.12.1239_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0006-8993(94)90796-X","article-title":"Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration","volume":"662","author":"Papa","year":"1994","journal-title":"Brain Res"},{"key":"10.4065\/74.12.1239_bib10","first-page":"394","article-title":"The long-duration action of levodopa may be due to a postsynaptic effect","volume":"20","author":"Barbato","year":"1997","journal-title":"Clin Neuro-pharmacol"},{"issue":"suppl 5","key":"10.4065\/74.12.1239_bib11","first-page":"SI7","article-title":"Levodopa therapy: consequences of the nonphysiologic replacement of dopamine","volume":"50","author":"Chase","year":"1998","journal-title":"Neurology"},{"issue":"suppl 1","key":"10.4065\/74.12.1239_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199855001-00001","article-title":"The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease","volume":"55","author":"Chase","year":"1998","journal-title":"Drugs"},{"key":"10.4065\/74.12.1239_bib13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ana.410270105","article-title":"Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease","volume":"27","author":"Mouradian","year":"1990","journal-title":"Ann Neurol"},{"key":"10.4065\/74.12.1239_bib14","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/ana.410320611","article-title":"Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease","volume":"32","author":"Baronti","year":"1992","journal-title":"Ann Neurol"},{"key":"10.4065\/74.12.1239_bib15","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/archneur.1994.00540240080020","article-title":"Fluctuating Parkinson's disease: treatment with the long-acting dopamine agonist cabergoline","volume":"51","author":"Ahlskog","year":"1994","journal-title":"Arch Neural"},{"key":"10.4065\/74.12.1239_bib16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00002826-199619030-00002","article-title":"Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect","volume":"19","author":"Ahlskog","year":"1996","journal-title":"Clin Neuropharmacol"},{"key":"10.4065\/74.12.1239_bib17","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0025-6196(12)62690-1","article-title":"Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease","volume":"63","author":"Ahlskog","year":"1988","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/74.12.1239_bib18","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1212\/WNL.43.5.1036","article-title":"Oral levodopalcarbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study","volume":"43","author":"Kurth","year":"1993","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib19","first-page":"484","article-title":"The stability characteristics of levodopa solution [abstract]","volume":"9","author":"Pappert","year":"1994","journal-title":"Mov Disord"},{"key":"10.4065\/74.12.1239_bib20","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archneur.1987.00520220012007","article-title":"Plasma levels of amino acids correlate with motor fluctuations in parkinsonism","volume":"44","author":"Pincus","year":"1987","journal-title":"Arch Neural"},{"key":"10.4065\/74.12.1239_bib21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0014-2999(96)00454-2","article-title":"Inhibition of dopamine neuron firing by pramipexole, a dopamine 03 receptor-preferring agonist: comparison to other dopamine receptor agonists","volume":"312","author":"Piercey","year":"1996","journal-title":"Eur J Pharmacal"},{"issue":"suppl 4","key":"10.4065\/74.12.1239_bib22","first-page":"A134","article-title":"Binding and functional potencies of bromocriptine, pramipexole, pergolide and ropinirole at 0,0, and 0 receptors [abstract]","volume":"50","author":"Perachon","year":"1998","journal-title":"Neurology"},{"issue":"supp1 1","key":"10.4065\/74.12.1239_bib23","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1212\/WNL.49.1_Suppl_1.S58","article-title":"Pharmacologic profile of ropinirole: a nonergoline dopamine agonist","volume":"49","author":"Tulloch","year":"1997","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/286157a0","article-title":"The role of 0-1 and 0-2 receptors","volume":"286","author":"Schachter","year":"1980","journal-title":"Nature"},{"key":"10.4065\/74.12.1239_bib25","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1001\/archneur.1992.00530290152026","article-title":"Dopamine agonist treatment of fluctuating parkinsonism: 0-2 (controlled-release MK-458) vs combined 0-1 and 0-2","volume":"49","author":"Ahlskog","year":"1992","journal-title":"Arch Neurol"},{"key":"10.4065\/74.12.1239_bib26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00023210-199605050-00006","article-title":"Comparative review of dopamine receptor agonists in Parkinson's disease","volume":"5","author":"Vitti","year":"1996","journal-title":"CNS Drugs"},{"key":"10.4065\/74.12.1239_bib27","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1212\/WNL.34.7.983","article-title":"Pergolide in the treatment of Parkinson's disease","volume":"34","author":"Mear","year":"1984","journal-title":"Neurology"},{"issue":"suppl 1","key":"10.4065\/74.12.1239_bib28","first-page":"98","article-title":"Single dose response to pramipexole in patients with Parkinson's disease [abstract]","volume":"7","author":"Albani","year":"1992","journal-title":"Mov Disord"},{"key":"10.4065\/74.12.1239_bib29","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1212\/WNL.51.4.1057","article-title":"A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease [published correction appears in Neurology. 1999;52: 435]","volume":"51","author":"Lieberman","year":"1998","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib30","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00003495-199039030-00009","article-title":"Pergolide: a review of its pharmacological properties and therapeutic potential in Parkinson's disease","volume":"39","author":"Langtry","year":"1990","journal-title":"Drugs"},{"key":"10.4065\/74.12.1239_bib31","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.33.8.1009","article-title":"Comparison of pergoIide and bromocriptine therapy in parkinsonism","volume":"33","author":"LeWitt","year":"1983","journal-title":"Neurology"},{"issue":"suppl 3","key":"10.4065\/74.12.1239_bib32","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1212\/WNL.45.3_Suppl_3.S13","article-title":"Pergolide in the treatment of Parkinson's disease","volume":"45","author":"Mizuno","year":"1995","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib33","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/mds.870090409","article-title":"aPergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study","volume":"9","author":"Pezzoli","year":"1994","journal-title":"Mov Disord"},{"key":"10.4065\/74.12.1239_bib34","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1212\/WNL.49.4.1060","article-title":"Double-blind comparison of pramipexole and bromo-criptine treatment with placebo in advanced Parkinson's disease","volume":"49","author":"Guttman","year":"1997","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/mds.870130112","article-title":"Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study","volume":"13","author":"Korczyn","year":"1998","journal-title":"Mov Disord"},{"key":"10.4065\/74.12.1239_bib36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/mds.870070103","article-title":"Core assessment program for intracerebral transplantations (CAPIT)","volume":"7","author":"Langston","year":"1992","journal-title":"Mov Disord"},{"key":"10.4065\/74.12.1239_bib37","first-page":"225","article-title":"The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease","volume":"45","author":"Molho","year":"1995","journal-title":"J Neural Transm Suppl"},{"key":"10.4065\/74.12.1239_bib38","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1212\/WNL.49.1.162","article-title":"Clinical evaluation of prami-pexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study","volume":"49","author":"Lieberman","year":"1997","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib39","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/jnnp.66.4.436","article-title":"Oertel WHo Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study","volume":"66","author":"Pinter","year":"1999","journal-title":"J Neurol Neurasurg Psychiatry"},{"key":"10.4065\/74.12.1239_bib40","first-page":"231","article-title":"Ropinirole in the symptomatic treatment of Parkinson's disease","volume":"45","author":"Brooks","year":"1995","journal-title":"J Neural Transm Suppl"},{"key":"10.4065\/74.12.1239_bib41","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00002826-199619030-00005","article-title":"Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease","volume":"19","author":"Rascol","year":"1996","journal-title":"Clin Neuropharmacol"},{"key":"10.4065\/74.12.1239_bib42","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/mds.870090107","article-title":"A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease","volume":"9","author":"Olanow","year":"1994","journal-title":"Mov Disord"},{"key":"10.4065\/74.12.1239_bib43","first-page":"95","article-title":"Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease","volume":"37","author":"Lieberman","year":"1983","journal-title":"Adv Neurol"},{"key":"10.4065\/74.12.1239_bib44","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1212\/WNL.35.5.749","article-title":"Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide","volume":"35","author":"Goetz","year":"1985","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib45","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/jnnp.51.4.529","article-title":"Parkinson's disease: an open label trial of pergolide in patients failing bromo-criptine therapy","volume":"51","author":"Factor","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"suppl 1","key":"10.4065\/74.12.1239_bib46","first-page":"314","article-title":"Olanow CWo Pergolide\/parlodel crossover study [abstract]","volume":"38","year":"1988","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib47","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1212\/WNL.39.8.1121","article-title":"Agonist substitution in advanced Parkinson's disease","volume":"39","author":"Goetz","year":"1989","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib48","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1212\/WNL.52.6.1227","article-title":"Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow?","volume":"52","author":"Goetz","year":"1999","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib49","first-page":"493","article-title":"Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics of L-DOPA","volume":"69","author":"Nutt","year":"1996","journal-title":"Adv Neurol"},{"key":"10.4065\/74.12.1239_bib50","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1212\/WNL.43.12.2685","article-title":"Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa\/carbidopa action in parkinsonian patients","volume":"43","author":"Roberts","year":"1993","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib51","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.60.1.36","article-title":"Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations","volume":"60","author":"Ruottinen","year":"1996","journal-title":"J Neural Neurosurg Psychiatry"},{"key":"10.4065\/74.12.1239_bib52","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1212\/WNL.44.5.913","article-title":"Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinclics and pharmacodynamics of lcvodopa in parkinsonian patients","volume":"44","author":"Nutl","year":"1994","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib53","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00002826-199619030-00004","article-title":"Effect of one month's treatment with peripherally acting calechol-O-methyltransferase inhibitor, enlacapone, on pharmacokinelics and motor response to levodopa in advanced parkinsonian patients","volume":"19","author":"Ruottinen","year":"1996","journal-title":"Clin Neuropharmacol"},{"key":"10.4065\/74.12.1239_bib54","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.410420511","article-title":"Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients [published correction appears in Ann Neural. 1998;44:292]","volume":"42","author":"Parkinson Study Group","year":"1997","journal-title":"Ann Neurol"},{"key":"10.4065\/74.12.1239_bib55","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","article-title":"Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations","volume":"51","author":"Rinne","year":"1998","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib56","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/jnnp.63.4.421","article-title":"Catechol-O-methyltransferase inhibition with tolcapone reduces the \u201cwearing off\u201d phenomenon and levodopa requirements in fluctuating parkinsonian patients","volume":"63","author":"Baas","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.4065\/74.12.1239_bib57","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.49.4.1066","article-title":"Tolcapone improves motor function in parkinsonian patients with the wearing-off phenomenon: a double-blind, placebo-controlled, multicenter trial","volume":"49","author":"Rajput","year":"1997","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib58","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/archneur.55.8.1089","article-title":"Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa","volume":"55","author":"Adler","year":"1998","journal-title":"Arch Neurol"},{"key":"10.4065\/74.12.1239_bib59","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/1531-8257(199901)14:1<38::AID-MDS1008>3.0.CO;2-I","article-title":"Efficacy and tolerabilily of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients","volume":"14","author":"Tolcapone Study Group","year":"1999","journal-title":"Mov Disord"},{"key":"10.4065\/74.12.1239_bib60","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00002826-198802000-00004","article-title":"Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease","volume":"11","author":"Golbc","year":"1988","journal-title":"Clin Neuropharmacol"},{"key":"10.4065\/74.12.1239_bib61","first-page":"163","article-title":"Patterns of dystonia (\u201cI-DI\u201d and \u201cD-L-D\u201d) in response to L-dopa therapy for Parkinson's disease","volume":"52","author":"Muenter","year":"1977","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/74.12.1239_bib62","first-page":"309","article-title":"3-O-methyldopa in Parkinson's disease","volume":"5","author":"Muenter","year":"1974","journal-title":"Adv Neurol"},{"key":"10.4065\/74.12.1239_bib63","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/mds.870110319","article-title":"High-dose pergolide monoiherapy in the treatment of severe levodopa-induced dyskinesias [letter]","volume":"11","author":"Facca","year":"1996","journal-title":"Mov Disord"},{"issue":"suppl 2","key":"10.4065\/74.12.1239_bib64","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1212\/WNL.51.2_Suppl_2.S30","article-title":"Neostriatal mechanisms in Parkinson's disease","volume":"51","author":"Chase","year":"1998","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib65","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Verhagcn Metman","year":"1998","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib66","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.46.6.1548","article-title":"Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease","volume":"46","author":"Carpentier","year":"1996","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib67","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1212\/WNL.45.4.753","article-title":"Stcreotactic ventral palli-dotomy for Parkinson's disease","volume":"45","author":"Dogali","year":"1995","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib68","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/ana.410440615","article-title":"Bilateral high-frequency stimulation of the internal globus pallidus in advanced Parkinson's disease","volume":"44","author":"Volkmann","year":"1998","journal-title":"Ann Neurol"},{"key":"10.4065\/74.12.1239_bib69","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1212\/WNL.51.3.850","article-title":"Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease","volume":"51","author":"Kumar","year":"1998","journal-title":"Neurology"},{"issue":"suppl 2","key":"10.4065\/74.12.1239_bib70","first-page":"A222","article-title":"A novel treatment for transient freezing in Parkinson's disease: application of a laser pointer [abstract]","volume":"52","author":"Zhang","year":"1999","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib71","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/mds.870050311","article-title":"Evaluation of a modified inverted walking stick as a treatment for parkinsonian freezing episodes","volume":"5","author":"Dietz","year":"1990","journal-title":"Mov Disord"},{"key":"10.4065\/74.12.1239_bib72","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/syn.890180203","article-title":"Slow recovery of human brain MAO B after L-deprenyl (Selcgeline) withdrawal","volume":"18","author":"Fowler","year":"1994","journal-title":"Synapse"},{"issue":"suppl 3","key":"10.4065\/74.12.1239_bib73","first-page":"SI0","article-title":"Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment","volume":"52","author":"Wolters","year":"1999","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib74","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/ana.410060409","article-title":"Dementia in Parkinson disease","volume":"6","author":"Lieberman","year":"1979","journal-title":"Ann Neurol"},{"key":"10.4065\/74.12.1239_bib75","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1001\/archneur.1988.00520270034017","article-title":"An estimate of the prevalence of dementia in idiopathic Parkinson's disease","volume":"45","author":"Maycux","year":"1988","journal-title":"Arch Neurol"},{"key":"10.4065\/74.12.1239_bib76","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1212\/WNL.52.9.1908","article-title":"Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole","volume":"52","author":"Frucht","year":"1999","journal-title":"Neurology"},{"key":"10.4065\/74.12.1239_bib77","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4065\/74.4.371","article-title":"Constric-tivc pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease","volume":"74","author":"Ling","year":"1999","journal-title":"Mayo Clin Proc"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561961164158X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561961164158X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T08:50:58Z","timestamp":1545468658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002561961164158X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,12]]},"references-count":77,"journal-issue":{"issue":"12","published-print":{"date-parts":[[1999,12]]}},"alternative-id":["S002561961164158X"],"URL":"https:\/\/doi.org\/10.4065\/74.12.1239","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[1999,12]]}}}